This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This is a Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 ( R-flurbiprofen, or Flurizan) on Measures of Cognition, Activities of Daily Living, and Global Function in Subjects with Mild Dementia of the Alzheimer's Type. The primary objective is to evaluate the change in cognition and activities of daily living, as measured by ADAS-cog, and ADCS-ADL in subjects with Alzheimer's disease treated with MPC-7869. The secondary objective is to assess changes in cognition as measured by a Neuropsychological Test Battery (NTB) and to assess changes in global function as measured CDR-sb. The exploratory objectives are to assess changes in quality of life of Alzheimer's disease patients and their caregivers as measured by the Quality of life -Alzheimer's Disease Scale (QOL-AD) and the Caregiver Burden Inventory; to assess the impact of treatment with MPC-7869 on healthcare resource use and caregiver time spent using the Resource Utilization In Dementia (RUD) Lite Questionnaire. Additional Observations: Safety of treatment with MPC-7869; Cerebrospinal fluid (optional) and peripheral blood analysis for potential biomarkers; Population pharmacokinetics of MPC-7869.This parallel group study will compare the safety and efficacy of daily dosing of 800 mg twice daily MPC-7869 to placebo.Study subjects will be stratified at randomization according to use/nonuse of acetylcholinesterase inhibitors and/or memantine, and treated for 18 months. The number of participants to be enrolled at this site is 30-40. The total duration of the study is 20 months per participant

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
2M01RR000533-39
Application #
7606297
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2007-01-03
Project End
2007-11-30
Budget Start
2007-01-03
Budget End
2007-11-30
Support Year
39
Fiscal Year
2007
Total Cost
$1,737
Indirect Cost
Name
Boston University
Department
Administration
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Guan, Yue; Roter, Debra L; Wolff, Jennifer L et al. (2018) The impact of genetic counselors' use of facilitative strategies on cognitive and emotional processing of genetic risk disclosure for Alzheimer's disease. Patient Educ Couns 101:817-823
Altman, Matthew C; Whalen, Elizabeth; Togias, Alkis et al. (2018) Allergen-induced activation of natural killer cells represents an early-life immune response in the development of allergic asthma. J Allergy Clin Immunol 142:1856-1866
Berti, Alvise; Warner, Roscoe; Johnson, Kent et al. (2018) Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol 70:1114-1121
Christensen, Kurt D; Uhlmann, Wendy R; Roberts, J Scott et al. (2018) A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone. Genet Med 20:132-141
Kattan, Meyer; Bacharier, Leonard B; O'Connor, George T et al. (2018) Spirometry and Impulse Oscillometry in Preschool Children: Acceptability and Relationship to Maternal Smoking in Pregnancy. J Allergy Clin Immunol Pract 6:1596-1603.e6
Rhee, Rennie L; Davis, John C; Ding, Linna et al. (2018) The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. Clin J Am Soc Nephrol 13:251-257
Liebschutz, Jane M; Buchanan-Howland, Kathryn; Chen, Clara A et al. (2018) Childhood Trauma Questionnaire (CTQ) correlations with prospective violence assessment in a longitudinal cohort. Psychol Assess 30:841-845
Wallace, Zachary S; Miloslavsky, Eli M; Cascino, Matthew et al. (2017) Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken) 69:1004-1010
Gern, James E; Calatroni, Agustin; Jaffee, Katy F et al. (2017) Patterns of immune development in urban preschoolers with recurrent wheeze and/or atopy. J Allergy Clin Immunol 140:836-844.e7
Guan, Yue; Roter, Debra L; Erby, Lori H et al. (2017) Disclosing genetic risk of Alzheimer's disease to cognitively impaired patients and visit companions: Findings from the REVEAL Study. Patient Educ Couns 100:927-935

Showing the most recent 10 out of 476 publications